Takeda announces closing of partnership with Innovent Biologics for oncology medicines

Following the completion of the transaction, Takeda has acquired certain rights to IBI363 and IBI343, two next-generation, late-stage investigational oncology medicines, worldwide outside of Greater China. IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. These investigational medicines have the potential to address unmet needs for patients with a range of solid tumors.

Takeda will lead global co-development and U.S. co-commercialization of IBI363 and has exclusive commercialization rights outside the U.S. and Greater China. Takeda also has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S. For IBI343, Takeda has exclusive rights to develop, manufacture and commercialize worldwide, outside of Greater China. Takeda intends to establish manufacturing for these investigational medicines in the U.S.

"Our collaboration with Innovent reflects the power of partnerships in oncology," said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. "By combining innovative science with global development and commercialization expertise, we can advance more options for patients with the potential to address critical treatment gaps. This agreement reflects our deep commitment to developing medicines that enhance and extend the lives of people living with cancer."

As part of the agreement, Takeda also has an exclusive option to license global rights to IBI3001, an early-stage investigational medicine, outside of Greater China.

Takeda will pay Innovent US$1.2 billion upfront per the terms of the agreement before the end of Takeda’s fiscal year, ending March 31, 2026. This will include an equity investment of US$100 million in Innovent by Takeda. The financial impact of the deal for the fiscal year ending March 31, 2026 has been reflected in Takeda’s revised forecast announced on October 30, 2025.